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Background: Erectile dysfunction (ED) is a well-documented medical condition that is expected 
to increase significantly over the next several decades, especially as men live longer and the 
prevalence of diabetes and cardiovascular diseases increase. Pharmacology agents are often the 
first line treatment approach. Newer solid dosage forms, known as orally disintegrating tablets 
(ODT), are now available as one treatment option.
Objectives: To review the drug delivery mechanisms of ODTs in general and to review safety and 
efficacy of vardenafil ODT (a PDE-5 inhibitor) as a treatment option for management of ED.
Method: Literature reviews were performed of pharmaceutical dosage forms and the POTENT 
I (n = 358 subjects) and POTENT II (n = 337 subjects) studies that investigated vardenafil 
ODT.
Results: Vardenafil ODT has been successfully used in multiple age groups and in multiple 
settings with men from various ethnic backgrounds. Efficacy of vardenafil ODT, as measured 
using the International Index of Erectile Function (IIEF-EF) and from the Sexual Encounter 
Profile (SEP) was significantly greater than placebo (P , 0.0001) at 12 weeks. Safety profiles 
were similar to film-coated dosage forms with no patient deaths reported.
Conclusion: Vardenafil ODT offers a convenient, ready-to-use approach for combating ED. 
Safety concerns are similar to other PDE-5 inhibitors and practitioners should counsel patients 
accordingly.
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Introduction
Both the National Institutes of Health and the American Urological Association define 
erectile dysfunction (ED) as the inability to achieve, maintain, or sustain an erection 
firm enough for sexual intercourse. ED is a complex condition that negatively impacts 
men’s self-esteem, quality of sexual satisfaction, and interpersonal relationships, and 
impedes in other quality of life areas.1 The etiology of ED is equally complex;   increasing 
age, concomitant diseases (eg, cardiovascular disorders, hyperlipidemia, endocrine 
disorders, psychological disorders), obesity, prior surgeries (eg,   prostatectomy) are 
well known causes.2 Other patient risk factors for ED include alcohol use, tobacco 
use, and illicit drug use. Pharmaceutical use is also a factor as many commonly used 
products contribute to ED (Table 1).
ED is recognized worldwide. The Massachusetts Male Aging Study (MMAS) from 
the United States provides estimates of ED. Authors of the original research reported 
that 8% of males in the fourth decade of life had ED and that burden increased to nearly 
40% by the time males reached the age of 60 to 69 years. Worldwide, it is expected Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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that nearly 322 million men will experience ED by the year 
2025, an upward trend that is associated with life longevity 
and increased prevalence of diabetes.3
Clinicians’ understanding of ED has increased signifi-
cantly over the past 20 years through better knowledge of the 
peripheral physiology of penile erections.4 ED can be classi-
fied as either organic or psychogenic.5 Organic   classifications 
include arteriogenic, cavernosal, or mixed; neurogenic; 
anatomic; and endocrinologic. Psychogenic classifications 
include generalized or situational. Causes of ED are not 
mutually exclusive.6
Pathophysiology
An erection is under control of the autonomic nervous system 
(ANS), but can also be stimulated or inhibited by central ner-
vous inputs.7 Mechanoreceptors of the penis, through stimula-
tion, elicit parasympathetic nerves of the ANS to relax in the 
walls of penile arterioles. Arousal also increases the release of 
nitric oxide from noncholinergic and nonadrenergic parasym-
pathetic nerve endings in the arterial walls and sinusoid of 
the penile corpora cavernosa. Nitric oxide is a catalyst for the 
enzyme, cyclic guanosine monophosphate (cGMP). Its effect 
is noted in relaxing the smooth muscle, which reduces the 
resistance of the blood flow into the penis, thereby increasing 
the amount of blood flow into the corpora cavernosa. There 
is a corresponding inhibition of sympathetic nerves. The 
small arterioles leading to the cavernous sinuses contract and 
reduce blood flow. The smooth muscles regulating the blood 
vessels also contract. Removal of cGMP is accomplished 
with the enzyme phosophodiesteras-5 (PDE-5). Inhibition 
of PDE-5 decreases metabolism of cGMP, an action that 
increases smooth muscle relaxation and maintenance of the 
blood flow into the erect penis.8
Pharmacology treatment options  
for ED
First line pharmacology treatment options for ED are 
PDE-5 Inhibitors, with sildenafil, tadalafil, and vardenafil 
being the three most widely used. The US Food and Drug 
  Administration approved the first PDE-5 inhibitor in 1998. 
This class of agents works by selectively inhibiting PDE-5; 
an action that increases and or preserves the cGMP levels in 
the penis. As a result, erections may last longer.
PDE-5 inhibitor products are intended for oral 
  administration and are manufactured in solid dosage form. 
All of the PDE-5 inhibitor products are available as unscored, 
film-coated tablets and in a variety of strengths. Vardenafil, 
while available in a film-coated tablet, is the one product also 
available as an oral disintegrating tablet (ODT).   Clinicians 
are encouraged to recognize characteristics of ODTs and 
incorporate that information when prescribing products 
with multiple dosage forms. The purpose of this article is to 
explore the benefits of ODTs in general and especially within 
the management of ED.
Routes of administration
According to the United States Pharmacopeia, tablets are solid 
dosage forms in which the active pharmaceutical ingredient 
(API) is blended with excipients and compressed into final 
form which, unless otherwise indicated, conveys the meaning 
of immediate release. This dosage form is generally intended 
for swallowing. Another dosage form, ODT, is meant for 
rapid disintegration within the mouth to provide dispersion 
before swallowing.9 In the European   Pharmacopeia, this 
type of dosage form is known as   orodisperse.10 V  arious other 
words (eg, rapid dissolving, rapid disintegration, mouth 
d  issolving) convey the same intent and may be used by 
di  fferent   manufacturers in marketing.
ODTs entered the market in the 1980s as an alternative 
to tablets or other conventional dosage forms (eg, capsules, 
lozenges, syrups, elixirs).11 There remains a continued inter-
est for further ODT product development stemming from the 
need for noninvasive delivery systems, accurate dosing, and 
to facilitate patient compliance.11,12
Patient factors
Many patient factors make ODTs suitable, including 
impaired swallowing, inconvenience of swallowing large 
amounts of liquid, or pre-existing nausea. Dysphagia or 
difficulty swallowing is common in the general popula-
tion, about 35% being affected at some point.12 Dysphagia 
increases in patients with advancing age or certain medical 
Table  1  Common  classes  of  drugs  associated  with  erectile 
dysfunction
Drug class Examples of specific drugs
Antihypertensives Alpha-adrenergic agonists
Beta blockers (nonselective)
Calcium-channel blockers
Diuretics Aldosterone antagonists
Thiazide diuretics
Psychiatric agents Benzodiazepines
Butyrophenones
Selective serotonin reuptake inhibitors
Tricyclic antidepressants
Cardiac glycosides Digitalis preparations
Steroid agents
Neoplastic agents Leuprolide
Note: Data from Hatzichristou DG, Pescatori eS. Current treatments and emerging 
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conditions (eg, cerebral vascular accident). Patients with 
advanced liver dysfunction may also find ODTs suitable, as 
these drugs avoid first pass effect.
Drug property factors
Characteristics of the API also contribute to the   suitability 
of ODTs. Ideally, an ODT does not require water for 
administration; disintegrates within a few seconds (,30); 
allows for high-drug loading; has no unpleasant after taste; 
is not affected by environmental conditions of humidity 
(hygroscopicity) or wide temperature variation; and is cost 
effective.11,12
Another important consideration is porosity. Faster 
absorption of water into an ODT tablet results in faster 
disintegration, a measure of tablet strength and structure. 
The ideal ODT has sufficient porosity and avoids becoming 
soft, friable, or unsuitable for packaging in blister packs.12 
A related concept here is wetting time. The lower the wetting 
time, the faster the disintegration.
Final considerations of ideal ODTs must include the 
bioavailability and onset of action, two attributes more 
closely related to ODTs than the other solid dosage forms. 
As dispersion through saliva occurs, pregastric absorption 
also occurs. Decreased saliva may slow the rate of disintegra-
tion and may decrease bioavailability.11 Reductions in side 
effects from products with ODTs has also been reported.12 
ODTs offer superior dosing accuracy compared with other 
oral forms such as liquids or elixirs.
Medications that require large amounts of liquid would 
not be suitable for ODT. Medications that have either short 
half-lives (those requiring frequent administration) or 
sustained-release formulation would also be unsuitable.
Patient compliance and acceptance
Patient compliance has increased as a result of ODTs. 
Various clinical trials in a variety of clinical conditions 
(eg, allergy, psychiatry, migraine headaches) have estab-
lished an increase in compliance to dosing regimens for 
medications delivered via ODT.12 Patients report that the 
ODTs were well-tolerated and just as effective as conven-
tional tablets.
Patient preference may influence compliance. It has been 
reported that, for easy swallowing, the optimal tablet size 
should not exceed 8 mm. For ease of tablet handling, however, 
the size should be greater than 8 mm,11 resulting in a tension 
between ease of handling and ease of   swallowing. ODTs 
overcome this paradox by eliminating the need for swallowing 
and the size may contribute to patient preference.
Vardenafil orally disintegrating  
tablet
Vardenafil ODT (scheduled for release in the United States in 
2011) carries the indication for treatment of ED and is gener-
ally taken up to 1 hour before sexual activity. Vardenafil ODT 
shares many positive attributes with other ODTs. Its unique 
blister-pack packaging protects the structural integrity of the 
tablet and retards excessive humidity. Packaging in boxes of 
4 tablets with easy opening peel-back containers is easier to 
handle than tamper-proof bottles, especially if the individual 
has arthritic hands or other impairments. Because of the pack-
age size, the product can be transported in original containers – 
another important safety feature. Film-coated tablets offer 
the opportunity to remove the product from the tamper-proof 
container and store it in a pocket or other container. Safety 
experts generally agree that leaving the product in its original 
packaging ensures accurate product identification.
The pharmacokinetics of vardenafil ODT, compared 
with the standard film-coated pill dosage form, demonstrates 
a higher systemic exposure. The time to reach Cmax was 
1.5 hours and was 15% higher than the film-coated tablet. 
There appears to be no effect on peak onset after consump-
tion of high fat meals. However, swallowing the ODT with 
water has reduced the area under the curve (AUC) by 29%.
Efficacy and safety
The POTENT I and POTENT II studies, conducted in more 
than 30 centers around the world, provide evidence of the 
efficacy for vardenafil ODT. Both studies included a fair 
representation of men over the age of 65 years – notable 
given the prior under-representation of this age group in 
other PDE-5 inhibitor studies.
In the POTENT I study, with an enrolled sample of 
409 men with ED and 355 completing the study, efficacy was 
measured using two instruments: the International Index of 
Erectile Function (IIEF-EF), and two questions (Numbers 2 
and 3) from the Sexual Encounter Profile (SEP).13 Subjects 
with ED were recruited into either the less than 65 years age 
group or the greater than 65 years group. White males com-
prised the largest number of subjects. Nearly half of all subjects 
had an organic etiology for ED (Table 2). The study investi-
gators found a statistically significant difference between the 
vardenafil group and the placebo group (P , 0.0001) for all 
three measures of efficacy (Table 3). The incidence and type 
of adverse event and effect of ODT vardenafil were similar 
to the film-coated dosage form and the most common adverse 
effects were headache and flushing (Table 4). No patient deaths 
were associated with vardenafil ODT.Patient Preference and Adherence 2011:5 submit your manuscript | www.dovepress.com
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Researchers involved in the POTENT II study conducted 
a double-blind, multicenter, randomized, parallel-group, 
placebo-controlled study in four countries.14 Data were col-
lected from 331 subjects with more than 50% of the sample 
being over the age of 65 years. Predominantly, white males 
and men with organic ED were represented in the sample. 
Efficacy was measured using the International Index of 
Erectile Function (IIEF-EF) as well as portions of the Sexual 
Encounter Profile. Statistically significant treatment effects 
were noted when comparing vardenafil group and the placebo 
group (P , 0.0001). As in the POTENT I study, side effects 
and adverse events were similar between the ODT vardenafil 
and the film-coated dosage form and differed from placebo. 
Headache and flushing were the most commonly reported 
adverse effects. By the end of the 12-week study period, there 
were no notable differences among a number of physiologi-
cal variables such as vital signs (including blood pressure), 
ECG changes, or other laboratory measures.14
Patient counseling: an essential  
safety element
Clinicians must be comfortable addressing ED with patients, 
and in some cases, must wait for cues from the patient.1,6 
  Clinicians have an important role in providing   information 
about vardenafil ODT to ED patients. One of the most 
  important roles of the clinician is to ensure that patients 
recognize that the 10 mg vardenafil ODT is not interchange-
able with the 10 mg vardenafil film-coated tablet as there are 
slight differences in pharmacokinetics. Should patients not 
experience sufficient outcomes with the ODT formulation, 
the film-coated tablet dosage form should be explored.
As with other PDE-5 inhibitor agents, there is a safety 
profile that should be understood by the patient and 
the clinician. This safety profile includes the thorough 
medical history, physical exam, a complete medication 
  reconciliation, and assessment of risk factors. Clinicians 
should recognize that structural deformities of the penis 
(eg,   Peyronie’s disease) are contraindications to this product 
class. Concomitant medications (Table 5) that have untow-
ard pharmacodynamic effects include nitrates (absolute 
contraindication), alpha-blockers, antihypertensives, and 
potent CYP3A4 inhibitors (cautions with regard to con-
comitant administration).
Patients should receive counseling on adverse effects. 
General adverse reactions have been reported with vardenafil 
ODT and mirror many adverse effects from PDE-5 inhibitors. 
The most common adverse reactions were headache, flushing, 
nasal congestion, dyspepsia, dizziness, and back pain. It is 
unknown if analgesia or antipyretic use prior to administering 
vardenafil ODT would reduce adverse effects.
Table 2 Demographic data findings from POTENT I and POTENT II
Variable POTENT I13 POTENT II14 Total
Age ,65 yrs $65 yrs ,65 yrs $65 yrs ,65 yrs $65 yrs
Subjects (n) 168 190 170 167 338 357
Race n (%) n (%) n (%) n (%) n (%) n (%)
  white 108 (64.3) 132 (69.5) 107 (62.9) 125 (74.9) 240 (71) 232 (65)
  Black 5 (3) 9 (4.7) 14 (8.2) 3 (1.8) 14 (4.1) 17 (4.8)
  Asian 8 (4.8) 5 (2.6) 8 (4.7) 5 (3) 13 (3.8) 13 (3.6)
  Missing 47 (28) 44 (23.2) 41 (24.1) 34 (20.4) 91 (26.9) 75 (21)
eD type n (%) n (%) n (%) n (%) n (%) n (%)
  Organic 77 (48.5) 110 (57.9) 98 (57.6) 121 (72.5) 187 (55.3) 219 (61.3)
  Psychogenic 30 (17.9) 11 (5.8) 25 (14.7) 4 (2.4) 41 (12.1) 29 (8.1)
  Mixed 60 (35.7) 68 (35.8) 41 (24.1) 38 (22.8) 128 (37.9) 79 (22.1)
  Missing 1 (0.6) 1 (0.5) 6 (3.5) 4 (2) 2 (0.6) 10 (2.8)
Table 3 POTENT I and POTENT II efficacy findings at 12 weeks 
by mean scores
Efficacy POTENT I13 POTENT II14
Placebo Vardenafil  
ODT
Placebo Vardenafil   
ODT
iieF-eF 14.4 21.5* 15.0 22.9*
SeP # 2 46.7 73.7* 48.8 76.1*
SeP # 3 26.7 64.9* 30.7 69.6*
Note: *Difference in mean scores statistically significant (P , 0.0001).
Abbreviations:  iieF-eF,  international  index  of  erectile  Function;  SeP,  Sexual 
Encounter Profile.
Table 4 Leading adverse eventsa from POTeNT i and POTeNT ii
Adverse event POTENT I13 POTENT II14
Placebo Vardenafil  
ODT
Placebo Vardenafil 
ODT
Headache 2 30 4 21
Flushing 0 14 2 13
Nasal congestion 0 3 1 8
Dyspepsia 0 7 0 3
Note: ain patients reporting more than 1% adverse events.Patient Preference and Adherence
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Patients should be healthy enough for sexual activity. 
Patients with significant unstable angina, hypotension, severe 
cardiac failure, recent stroke, or recent myocardial infarc-
tion15 must refrain from sexual activity until the condition 
is stable and allows physical exercise/sexual activity. From 
the genitourinary system, there is the recognition of risk 
for priapism (painful erection of more than 4 hours’ dura-
tion). A sudden loss of vision in one or both eyes warrants 
prompt evaluation, as does the sudden loss of hearing. With 
the emerging use and availability of many homeopathic and 
herbal supplements, patients must receive counseling to avoid 
combining various therapies in order to avoid potentiating 
adverse effects. Consumers who use vardenafil ODT should 
also recognize that the product affords no protection against 
sexually transmitted infections.
Patients should also be counseled on several other topics. 
For examples, the desirable effects of increased erection, 
quality, strength, and ejaculate should be anticipated. Patients 
should receive instruction on how to take the ODT, which is 
placed on the tongue and rapidly dissolves. Patients should 
not remove the medication from the original blister pack until 
ready to take – a major benefit of the packaging of vardenafil 
ODT. They should also be taught to avoid taking the medica-
tion with water as previously mentioned.
Summary
Today, numerous treatment options exist for ED; many are 
mechanical in nature and some are pharmaceutical. The 
pharmaceutical approach to ED has been well studied and 
appears to be well tolerated and should be the first-line 
therapeutic approach. This approach is also less invasive. 
As the broad range of patients who experience some form 
of ED materializes, clinicians will need a good knowledge 
of the wide range of treatment options4 as well as the safety 
and efficacy features of these options.
Vardenafil ODT is an important agent to treat ED. 
Because of the ease of use, ODTs will help men find an 
acceptable and appropriate treatment option.
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